GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Instil Bio Inc (NAS:TIL) » Definitions » ROA %

Instil Bio (Instil Bio) ROA % : -15.53% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Instil Bio ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Instil Bio's annualized Net Income for the quarter that ended in Dec. 2023 was $-51.70 Mil. Instil Bio's average Total Assets over the quarter that ended in Dec. 2023 was $332.95 Mil. Therefore, Instil Bio's annualized ROA % for the quarter that ended in Dec. 2023 was -15.53%.

The historical rank and industry rank for Instil Bio's ROA % or its related term are showing as below:

TIL' s ROA % Range Over the Past 10 Years
Min: -68.83   Med: -38.65   Max: -22.98
Current: -39.35

During the past 5 years, Instil Bio's highest ROA % was -22.98%. The lowest was -68.83%. And the median was -38.65%.

TIL's ROA % is ranked worse than
52.7% of 1556 companies
in the Biotechnology industry
Industry Median: -35.515 vs TIL: -39.35

Instil Bio ROA % Historical Data

The historical data trend for Instil Bio's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instil Bio ROA % Chart

Instil Bio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
-68.83 -22.98 -33.76 -40.87 -38.65

Instil Bio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -42.44 -50.21 -17.87 -72.06 -15.53

Competitive Comparison of Instil Bio's ROA %

For the Biotechnology subindustry, Instil Bio's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Instil Bio's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Instil Bio's ROA % distribution charts can be found below:

* The bar in red indicates where Instil Bio's ROA % falls into.



Instil Bio ROA % Calculation

Instil Bio's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-156.087/( (482.128+325.63)/ 2 )
=-156.087/403.879
=-38.65 %

Instil Bio's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-51.7/( (340.272+325.63)/ 2 )
=-51.7/332.951
=-15.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Instil Bio  (NAS:TIL) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-51.7/332.951
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-51.7 / 0)*(0 / 332.951)
=Net Margin %*Asset Turnover
=N/A %*0
=-15.53 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Instil Bio ROA % Related Terms

Thank you for viewing the detailed overview of Instil Bio's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Instil Bio (Instil Bio) Business Description

Traded in Other Exchanges
N/A
Address
3963 Maple Avenue, Suite 350, Dallas, TX, USA, 75219
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using our Co-Stimulatory Antigen Receptor, or CoStAR, platform. The company's lead product candidate, ITIL-168, is an autologous TIL therapy that it is initially developing for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma.
Executives
Timothy L. Moore officer: Chief Operating Officer C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Sumita Ray officer: Chief Legal and Admin Officer C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Nimish P Shah director 7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018
Jack Nielsen director, 10 percent owner C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vivo Capital Fund Ix, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Mcgaughy R Kent Jr director 500 CRESCENT COURT, SUITE 250, DALLAS TX 75201
Curative Ventures V Llc 10 percent owner 3963 MAPLE AVENUE, SUITE 390, DALLAS TX 75219
Bronson Crouch director, 10 percent owner, officer: CEO and Chairman C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
Vivo Capital Ix, Llc 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Sandeep Laumas officer: CFO and CBO 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Neil W Gibson director C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Gwendolyn Binder director C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Zachary Roberts officer: Chief Medical Officer C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
George Matcham director C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
Vijay Chiruvolu officer: Chief Technical Officer C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037

Instil Bio (Instil Bio) Headlines

From GuruFocus